Company Overview and News

 
CCJ / Cameco Corp. 6-K (Current Report of Foreign Issuer)

2018-07-26 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
CCJ

 
Cameco reports second quarter results and its decision to suspend production at McArthur River and Key Lake for an indeterminate duration

2018-07-25 globenewswire
SASKATOON, Saskatchewan, July 25, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) today reported its consolidated financial and operating results for the second quarter ended June 30, 2018 in accordance with International Financial Reporting Standards (IFRS).
CCO CCJ

 
Cameco annonce la nouvelle heure de diffusion de ses résultats du deuxième trimestre et de sa conférence téléphonique

2018-07-23 globenewswire
SASKATOON, Saskatchewan, 23 juill. 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) publiera ses résultats du deuxième trimestre à la clôture des marchés le mercredi 25 juillet 2018.
CCO CCJ

 
Ur-Energy May Benefit From Next Stage In Trade War

2018-07-22 seekingalpha
With the news of US starting to look at uranium imports, same as they did in the case of steel, Ur-Energy could benefit as a 100% US producer.
CCJ URG

117
CANADA STOCKS - TSX falls 0.65 percent, down for the week

2018-07-20 reuters - 2
NEW YORK, July 20 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 107.55 points, or 0.65 percent, to 16,435.46, the index also closed the week down 0.65 percent, snapping a two-week winning streak. * Leading the index were Cameco Corp, up 4.1 percent, Eldorado Gold Corp, up 3.5 percent, and Labrador Iron Ore Royalty Corp , higher by 3.1 percent. * Lagging shares were West Fraser Timber Co Ltd, down 8.
TWMJF ACB ELD IFSPF WEED ACBFF BDRPF LIFZF CCJ CGC EGO

 
Cameco Provides Updated Times for Q2 Results and Conference Call

2018-07-20 globenewswire
SASKATOON, Saskatchewan, July 20, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) will issue its second quarter results after markets close on Wednesday, July 25, 2018.
CCO CCJ

2
Uranium Tariffs Threaten Nuclear Plants Trump Is Trying to Save - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
EFR CCJ URG UUUU URE

 
Cameco répond au sujet de l’enquête initiée par le département du commerce américain dans le cadre de la « section 232 » concernant les importations d’uranium

2018-07-19 globenewswire
SASKATOON, Saskatchewan, 19 juill. 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) a répondu aujourd’hui à la décision prise par le département du commerce des États-Unis (DOC) de lancer une enquête afin de déterminer si la quantité et les circonstances d’importation d’uranium étranger aux États-Unis représentent une menace pour la sécurité nationale.
CCO CCJ

 
CCJ / Cameco Corp. 6-K (Current Report of Foreign Issuer)

2018-07-19 sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
CCJ

 
Cameco Responds to the US Department of Commerce Initiation of a Section 232 Investigation into Uranium Imports

2018-07-18 globenewswire
SASKATOON, Saskatchewan, July 18, 2018 (GLOBE NEWSWIRE) -- Cameco (TSX:CCO) (NYSE:CCJ) today responded to the decision by the United States Department of Commerce (DOC) to launch an investigation into whether the quantity and circumstances of foreign uranium imports into the US threaten to impair national security.
CCO CCJ

5
U.S. Probe Boosts Uranium Stocks, But the Street Is Conflicted - Bloomberg

2018-07-18 bloomberg - 3
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
UEC EFR CCJ UUUU

2
Azarga Uranium and URZ Energy Complete Merger

2018-07-05 globenewswire
VANCOUVER, British Columbia, July 05, 2018 (GLOBE NEWSWIRE) -- AZARGA URANIUM CORP. (TSX:AZZ) (FRA:P8AA) (OTCMKTS:PWURF) (“Azarga Uranium”) and URZ ENERGY CORP. (TSX-V:URZ) (OTCQB:URZZF) (“URZ Energy”) are pleased to announce the completion of the previously announced merger between the two companies. Azarga Uranium has acquired all of the issued and outstanding shares of URZ Energy for consideration of 2.
PWURF AZZ EFR CCJ UUUU

12
Azarga Uranium and URZ Energy Shareholders Approve Plan of Arrangement

2018-06-29 globenewswire
VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) -- AZARGA URANIUM CORP. (TSX:AZZ) (FRA:P8AA) (OTCMKTS:PWURF) (“Azarga Uranium”) and URZ ENERGY CORP. (TSX-V:URZ) (OTCQB:URZZF) (“URZ Energy”) are pleased to announce that all resolutions put forward at the annual general and special meeting of the shareholders of Azarga Uranium and the special meeting of URZ Energy, as further described in the joint information circular dated 31 May 2018, were approved by an overwhelming majority.
PWURF AZZ EFR CCJ UUUU

69
Uranium Mining: The Competitive Landscape

2018-06-25 seekingalpha - 1
The operators in the Athabasca Basin, Canada, enjoy the highest-grade uranium deposits and have a geological edge over other uranium districts.
PALAY PEN RIO LAM BLT AZZ TOEYF SYH PDN UEXCF PALAF NXE UEC EFR BMN LMRXF FSY DNN PWURF CVV RIO BBL GVXXF BHPLF FCU SYHBF DYLLF RIO NXGEF BKY ISENF CVVUF WSTRF RTPPF FOSYF TOE RTNTF CCJ UUUU DYL PENMF UWEFF KVLQF TGRUF MGAFF PDN BHPBF FCUUF EU URG DML BKY MGA PUMGF BHP BNNLF 9888 BHP LAM

15
Uranium Mining: The Inflection On The Horizon

2018-06-18 seekingalpha
After a 10-year-old downtrend, uranium price may finally see light at the end of the tunnel, with major producers cutting production.
PDN PALAY PALAF BOE PDN URG CCJ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 13321L108